Steve Heller

Steve is an accomplished Global Strategic Marketing Leader. He has developed successful Business, Therapeutic Area and Brand Strategies. Commercial leadership spans sales, sales management, product launch, training & development, marketing, new product development, and business development.As Principal of OncStrat LLC, Steve works with development stage oncology firms to align R&D and market needs to create a compelling, evidence-based brand story.
Steve’s commercial development leadership in oncology includes small molecules, proteins and monoclonal antibodies, cell therapy, immunotherapy, novel drug platforms, and biomarkers. He has worked in oncology therapeutics and supportive care, including co-development and regional assets. Steve has spoken at multiple cancer conferences and is the only marketer (non-scientist) honored to be a contributing author to CANCER MEDICINE. (Personalized Medicine in Oncology Drug Development, CANCER MEDICINE, Holland-Frei, 8th Edition – 2010)

Steve moved from Bristol Myers to J&J to join the management team at Ortho Biotech, a start-up division with $10MM in sales that eventually grew to >$3B. Steve had integral roles in multiple acquisitions and was the commercial lead in the licensing of Velcade, J&J’s first $1B oncology asset. As VP of Oncology/Virology Business Development, he served on the Management Board of Tibotec Therapeutics. Prior to leaving J&J in 2013, Steve was a leader in the development of the oncology strategy for Janssen Pharmaceuticals, currently one of the fastest growing oncology companies.

Steve’s brings a diverse background to his work – he has been a teacher in the inner city and an elected public official. He is a member of the Board of Trustees of Hunterdon County, NJ YMCA and does pro bono consulting for non-profits. Steve has a B.S. from the Pennsylvania State University and M.A. from Villanova University.